STOCK TITAN

Director Kurian (NYSE: CI) receives 782-share stock award

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

Kurian George reported acquisition or exercise transactions in this Form 4 filing.

Cigna Group director George Kurian received an award of 782 shares of common stock on April 22, 2026. The shares were granted at $0.00 per share, increasing his directly held position to 4,560 shares of Cigna Group common stock.

A footnote explains that his economic interest also includes hypothetical shares whose value is tied to Cigna Group stock but settled in cash upon separation from service, so these cash-settled units are not included in the reported share totals.

Positive

  • None.

Negative

  • None.
Insider Kurian George
Role null
Type Security Shares Price Value
Grant/Award Common Stock, $.01 Par Value 782 $0.00 --
Holdings After Transaction: Common Stock, $.01 Par Value — 4,560 shares (Direct, null)
Footnotes (1)
  1. [object Object]
Shares awarded 782 shares Common Stock grant on April 22, 2026
Grant price per share $0.00 per share Award of common stock to director
Shares owned after transaction 4,560 shares Director’s direct holdings following the award
Transaction type Grant, award, or other acquisition (Code A) Non-derivative common stock transaction
Common Stock, $.01 Par Value financial
"security_title: "Common Stock, $.01 Par Value""
hypothetical shares financial
"economic interest also includes hypothetical shares of common stock"
Section 16 filings regulatory
"please see the reporting person's Section 16 filings for The Cigna Group"
proxy statement regulatory
"The Cigna Group's proxy statement filed with the SEC on March 13, 2026"
A proxy statement is a document companies send to shareholders ahead of a meeting that lays out the items up for a vote—like who will sit on the board, executive pay, and major corporate decisions—and provides background so shareholders can decide how to cast their votes or appoint someone to vote for them. Think of it as an agenda plus a ballot and briefing notes, important because the outcomes can change control, strategy, and value.
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Kurian George

(Last)(First)(Middle)
900 COTTAGE GROVE ROAD

(Street)
BLOOMFIELD CONNECTICUT 06002

(City)(State)(Zip)

UNITED STATES

(Country)
2. Issuer Name and Ticker or Trading Symbol
Cigna Group [ CI ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirector10% Owner
Officer (give title below)Other (specify below)
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
04/22/2026
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock, $.01 Par Value04/22/2026A782A$04,560(1)D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Explanation of Responses:
1. The reporting person's economic interest in The Cigna Group securities also includes hypothetical shares of common stock, the value of which is tied directly to the value of The Cigna Group stock. Under the rules of the Securities and Exchange Commission (SEC), Table I excludes these hypothetical shares because they are settled in cash, rather than The Cigna Group stock, upon separation from service. For more information regarding these securities, please see the reporting person's Section 16 filings for The Cigna Group and pages 51-52 and 118 of The Cigna Group's proxy statement filed with the SEC on March 13, 2026.
Remarks:
Exhibit 24 - Power of Attorney
Tyler Gratton, attorney-in-fact04/24/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did Cigna Group (CI) director George Kurian report?

George Kurian reported receiving an award of 782 shares of Cigna Group common stock. The shares were granted at no cash cost to him and increased his directly held position, as shown in the filing’s post-transaction total ownership figure.

How many Cigna Group (CI) shares does George Kurian hold after this Form 4?

After the reported award, George Kurian directly owns 4,560 shares of Cigna Group common stock. This figure reflects his post-transaction holdings in Table I and does not include separate hypothetical, cash-settled units referenced in the accompanying footnote.

Was George Kurian’s Cigna Group (CI) stock award an open-market purchase?

No, the 782 shares were reported with transaction code "A," indicating a grant, award, or other acquisition rather than an open-market purchase. The transaction price is listed as zero, consistent with a company-awarded stock grant instead of a market trade.

What does the footnote about hypothetical Cigna Group (CI) shares mean?

The footnote states that Kurian’s economic interest also includes hypothetical shares tied to Cigna Group’s stock value but settled in cash upon separation. Because they are cash-settled, SEC rules exclude them from Table I, so they are not counted in the reported share totals.

Does this Cigna Group (CI) Form 4 show any stock sales by George Kurian?

No, the Form 4 only reports an acquisition of 782 common shares through a grant or award. The transaction summary shows one acquisition event and no reported sales, dispositions, or derivative exercises in this particular insider filing.